Biotech ETFs for an M&A Boom
May 16, 2012 at 12:30 PM EDT
Strong prospects for new drug approvals, a favorable M&A environment, and a positive fundamental outlook have the biotechnology industry looking healthy, according to S&P Capital IQ. Investors who want exposure to the overall sector should consider exchange traded funds to help mitigate...